Published in Health Business Week, November 24th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Valeant Pharmaceuticals.
Report 1: Valeant Pharmaceuticals International (VRX) announced that the Securities and Exchange Commission is conducting an informal inquiry regarding events and circumstances surrounding trading in the company's common stock and the public release of data from its first pivotal phase 3 trial for Viramidine.
In addition, the SEC requested data regarding the company's stock option grants since January 1, 2000 and information about the company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.